Clinical TrialsThe efti/pembro combination has shown a dramatic improvement in median overall survival over the standard of care in a major study, indicating its potential impact on cancer treatment.
Market PotentialImmutep's focus on developing LAG-3 for multiple oncology indications, combined with a market cap of $364MM, suggests considerable upside potential for its shares.
Product DevelopmentThe company's lead product candidate, eftilagimod alpha (efti), is a promising soluble LAG-3 for advanced cancers, providing innovative treatment options.